Shares of Bristol-Myers Squibb Company (BMY) traded 0.13 points or 0.26% higher at $49.29.The total intraday money flow for the shares came in at a disappointing $(-13.38) million. The total upticks amounted to $153.01 million and the total downticks were approximately $166.39 million, with the up/down ratio of 0.92. On a different note, the shares have seen 3.25% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $44.45 million in upticks and an outflow of $52.24 million in downticks. The up/down ratio for the block was found to be 0.85. The net money flow for the block transaction was $(-7.79) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Bristol-Myers Squibb Company has lost 0.52% in the last five trading days and dropped 15.1% in the last 4 weeks. Bristol-Myers Squibb Company has dropped 2.54% during the last 3-month period . Year-to-Date the stock performance stands at -15.1%. Bristol-Myers Squibb Company (NYSE:BMY) rose 0.26% or 0.13 points on Wednesday and made its way into the gainers of the day. After trading began at $49.13 the stock was seen hitting $49.32 as a peak level and $48.32 as the lowest level. The stock ended up at $49.29. The daily volume was measured at 16,021,890 shares. The 52-week high of the share price is $77.12 and the 52-week low is $46.01. The company has a market cap of $82,375 million.
Company has reported several Insider transactions to the SEC, on Sep 9, 2016, Lamberto Andreotti (director) sold 21,600 shares at 56.87 per share price.On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at 72.69 per share price.On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at 70.79 per share price.
Bristol-Myers Squibb Co Last issued its quarterly earnings results on Jan 26, 2017. The company reported $0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.66. The company had revenue of $5243.00 million for the quarter, compared to analysts expectations of $5133.31 million. The companys revenue was up 22.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Bristol-Myers Squibb Co was Upgraded by Jefferies to Buy on Dec 19, 2016.
Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.